Biospectra Sustainability Profile
Biospectra, Inc., headquartered in the United States, is a leading provider of high-quality raw materials for the biopharmaceutical industry. Founded in 2001, the company has established itself as a key player in the production of cell culture media, excipients, and custom manufacturing solutions, catering to the needs of biotechnology and pharmaceutical companies worldwide. With a strong focus on quality and compliance, Biospectra's core products are distinguished by their rigorous testing and validation processes, ensuring they meet the stringent requirements of regulatory bodies. The company operates primarily in the US, with significant reach in global markets, positioning itself as a trusted partner in the development of innovative therapies. Notable achievements include a commitment to sustainability and continuous improvement, reinforcing its reputation as a reliable source of biopharmaceutical materials.
DitchCarbon Score
How does Biospectra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biospectra's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biospectra's reported carbon emissions
In 2024, Biospectra, Inc. reported total carbon emissions of approximately 7,878,000 kg CO2e. This figure includes 4,734,000 kg CO2e from Scope 1 emissions, 1,313,000 kg CO2e from Scope 2 emissions, and 1,524,000 kg CO2e from Scope 3 emissions. In 2023, the company recorded total emissions of about 3,072,000 kg CO2e, with Scope 1 emissions at 171,000 kg CO2e, Scope 2 emissions at 1,212,000 kg CO2e, and Scope 3 emissions at approximately 1,609,728 kg CO2e. Biospectra has set ambitious reduction targets, committing to a 42% reduction in Scope 1 and Scope 2 emissions by 2028, in line with the Paris Agreement. This target is based on a 2022 baseline and aims to significantly lower their greenhouse gas emissions. Additionally, the company is focused on measuring and reducing its Scope 3 emissions as part of its sustainability strategy. These targets have been validated through the Science Based Targets initiative (SBTi), confirming that they align with the necessary reductions to limit global warming to 1.5°C. Biospectra's commitment to sustainability reflects its proactive approach in the pharmaceuticals, biotechnology, and life sciences sector, based in the United States.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 171,000 | 0,000,000 |
| Scope 2 | 1,212,000 | 0,000,000 |
| Scope 3 | 1,609,728 | 0,000,000 |
How Carbon Intensive is Biospectra's Industry?
How Carbon Intensive is Biospectra's Location?
Biospectra's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biospectra has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Holdings Corporation
Thermo Fisher Scientific
Frequently Asked Questions
Common questions about Biospectra's sustainability data and climate commitments